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Introduction:  microRNAs are a family of small non protein-coding RNAs. They are involved in post-
transcriptional gene regulation of their target genes. The deregulation of microRNAs has been linked to
cancer development and tumor progression. The aim of out study was to look for microRNA-141 as a
diagnostic and prognostic biomarker for prostate cancer.
Patients  and  methods: The study prospectively recruited 30 patients newly diagnosed with prostate cancer;
including 13 and 17 patients without and with metastases, respectively. Another 30 patients without prostate
cancer diagnosis were included as a control group. Real-time polymerase chain reaction analysis was done
for relative quantification of microRNA-141.
Results:  The present study showed that microRNA-141 was significantly upregulated in cancerous patients
compared to control group. Also it was significantly upregulated in patients with metastatic disease compared
to non-metastatic patients. Moreover, it was significantly correlating with serum PSA and Gleason score.
Conclusion:  Serum microRNA-141 could be a promising diagnostic and prognostic biomarker for prostate
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ntroduction
rostate cancer (PCa) is the second most common cancer in men
fter lung cancer, with nearly 1 million new cases being diagnosed
very year and accounts for ∼10% of all new cancer cases in men
orldwide [1]. Measurements of serum PSA and digital rectal exam-
nd hosting by Elsevier B.V. This is an open access article under the CC
348 R. Ali et al.
Table  1  Comparison between the prostate cancer patients (PCa) and controls according to different parameters.
No. (%) Range Mean ± SD Median IQR p
Age (years)
PCa (n = 30) 55–80 67.2 ± 6 67 62.8–70.3
0.389Controls (n = 30) 55–87 65.4 ± 9.2 63.5 57.8–57.8
Prostate volume (grams)
PCa (n = 30) 47–200 88.7 ± 30.1 89 67.8–102
<0.001Controls (n = 30) 30–112 55.4 ± 23.1 47.5 34.8–74.3
PSA (ng/ml)
PCa (n = 30) 4.8–105 37.1 ± 32.4 27 10.2–59.5
<0.001Controls (n = 30) 0.4–5 2.4 ± 1.2 2.5 1.2–3.3
miRNA-141
PCa (n = 30) 1.1–139.1 29.4 ± 43.7 7.2 2.4–67.7
<0.001Controls (n = 30) 0.2–7 1.5 ± 1.7 1.3 0.6–1.6
Metastasis
PCa (n = 30)
No 13 (43.3%) –
Yes 17 (56.7%)
Gleason score
PCa (n = 30) 6–9
Low risk (6) 15 (50%)
Intermediate risk (7) 6 (20%)
High risk (≥8) 9 (30%)




Age (years) 0.070 0.713
Prostate volume (grams) 0.181 0.338
PSA (ng/ml) 0.436* 0.016*



















































(ELISA) technique. The Serum ELISA kit (DRG Instrumentsrs: Spearman coefficient.
* Statistically significant at p ≤ 0.05.
nation (DRE) are still the main triggers for prostatic biopsy [2]. On
he other hand; PSA is organ but not cancer specific, and could
e elevated by many benign conditions [3]. Furthermore, PCa is
etectable in approximately 15% of men with normal PSA val-
es [4], and being subject to genetic variation explaining its low
ensitivity and specificity [5].
icroRNAs are a family of small non protein-coding RNAs of
pproximately 22 nucleotides in length. They are involved in
ost-transcriptional gene regulation of their target genes either by
irecting mRNA degradation or by inducing translational repression
hrough binding to complementary sequences in the 3′-untranslated
egion of mRNAs [6].
ach mature microRNA potentially controls many gene targets and
ach mRNA is regulated by multiple microRNAs. microRNAs are
nvolved in regulation of various biological functions such as cell
roliferation, differentiation, apoptosis and metabolism. Previous
tudies suggested a direct link between microRNAs and cancer,
s microRNAs can act as oncogenes or tumor-suppressor genes,
epending on the target genes that they regulate [7–9]. Existing
ata show the potential clinical utility of microRNAs as diagnos-






mportantly, microRNAs have also been detected in plasma, where
hey are remarkably stable and protected from endogenous RNAase
nzymatic activity [11]. These findings raised the possibility
hat circulating microRNAs can be considered as potential novel
arkers for the diagnosis and prognosis of many diseases including
ancer [12].
nalysis of microRNA signatures of a large number of tumor sam-
les revealed that microRNA-141 is downregulated in pancreatic
13], esophageal [14], gastric [15] and colorectal cancers [16]. On
he other hand; studies on PCa were sparse and with contradictory
utcomes.
he objective of the present study was to investigate the role of
icroRNA-141 for the diagnosis and prognosis of prostate cancer
n a group of our patients.
atients  and  methods
thical committee approval was obtained through Alexandria Uni-
ersity, Egypt before conducting the study, and all patients included
n the study were notified about our study protocol and its possible
uture benefits. This study was carried out on 60 individuals: Thirty
atients with prostate cancer, this group was further subdivided into;
3 PCa patients without metastasis and 17 PCa patients with metas-
asis. Thirty healthy individuals of matched age were included as
 control group. All patients were recruited through the outpatient
linic of urology department, Alexandria University; Egypt.
ll patients included in this study were subjected to detailed history
aking, DRE, PSA measurement and Prostate volume measure-
ent using ultrasound abdomen and pelvis. Total serum PSA level
as measured using an Enzyme-Linked Immunosorbent AssaymbH, Germany) was used. Cancerous patients had TRUS guided
rostatic biopsies and pelvic MRI. More radiological investigations
ere done to high risk patients to look for metastases.























Figure  1  ROC curve for serum PSA(ng/ml) 
Relative  quantification  of  serum  miRNA  141  expression  levels




Complementary DNA (cDNA) was synthesized using TaqMan
®
MiRNA Reverse Transcription Kit with miRNA specific primers
(Applied Biosystems, USA).
Real-time PCR was performed using Applied Biosystems





2×  Universal PCR Master Mix, and Syn-cel-miR-39 miS-
cript miRNA Mimic as a spike in control. Reagents were purchased
from Applied Biosystems, USA.
Expression of microRNA-141 was calculated using the comparative
cycle threshold (CT) method (2–CT) [17].
Statistical  analysis  of  the  data
Data were fed to the computer and analyzed using IBM SPSS soft-
ware package version 20.0. Student t-test was used to compare
two groups for normally distributed quantitative variables, while
ANOVA was used for comparing the three studied groups and
followed by Post Hoc test for pairwise comparison. Spearman coef-
ficient was used to correlate between quantitative variables. The
receiver operating characteristic (ROC) curve analysis was per-





iRNA-141 to predict PCa group from control.
nd to determine the best cutoff value. The diagnostic sensitiv-
ty, specificity and predictive values were calculated by 2 ×  2
ables Significance of the obtained results was judged at the 5%
evel.
esults
he mean age of cancerous and non-cancerous patients was
7.17 ±  5.99 years and 65.43 ±  9.15 years respectively (p 0.6). The
ean serum PSA in non-metastatic PCa, metastatic PCa and control
roup were 32.1 ±  34.8, 41 ±  31 and 2.4 ±  1.2 ng/ ml respectively
p < 0.001), with no statistical difference between the two cancerous
roups. The mean prostate volume was significantly lower in control
roup (55.4 ±  23.1) compared to non-metastatic PCa (79.5 ±  19.8)
nd metastatic PCa (95.7 ±  35) (p < 0.001). All non-metastatic PCa
atients had Gleason 6, while metastatic patients had Gleason 6, 7
nd >7 in 2, 6 and 9 patients respectively. Table 1 illustrates patients’
emographics.
he mean serum microRNA-141 for non-metastatic, metastatic
ca and control groups were 3.9 ±  3.8, 49 ±  50.2 and 1.5 ±  1.7
espectively, with statistical significant difference between the three
tudied groups (p < 0.001). Using Spearman correlation coeffi-
ients; there was a significant positive correlation between serum
icroRNA-141 expression level and each of serum PSA level and
leason score (Table 2). Serum microRNA-141 expression showed
 sensitivity and specificity of 93.33% and 80% at a cut-off value
f >1.57 for the diagnosis of PCa (Fig. 1). It also had a sensitivity

















































Figure  2  ROC curve for serum PSA(ng/ml) and m
nd specificity of 69.23% and 94.12% at a cut-off value of 2.79 for
redicting metastatic PCa (Fig. 2).
iscussion
xisting data show the potential clinical utility of microRNAs as
iagnostic, prognostic and predictive markers for aggressive and
etastatic cancers [10]. Alterations in microRNA expression can
ffect important cellular processes like cell cycle, proliferation or
poptosis, thus providing a direct link to cancer development and
rogression [18] . Selth et al. proposed that these microRNAs were
xpressed in prostate cancer cells and were released into the sur-
ounding blood vessels during disease progression [19].
he present study demonstrated that serum microRNA-141 lev-
ls were significantly elevated in patients with PCa, compared
o controls. ROC analyses for the diagnostic power of serum
icroRNA-141 yielded an AUC of 0.912 with 93.3% sensitivity
nd 80% specificity in differentiating patients with PCa from con-
rol group. This goes in agreement with Mitchell et al., where they
eported that circulating microRNA-141 can distinguish patients
ith PCa from healthy individuals with sensitivity and specificity
f 60% and 100% respectively [11].n the current study, we also investigated whether microRNA-
41 could be used to differentiate non metastatic from metastatic
Ca. Our analysis reported overexpression of serum microRNA-141
I
r
-141 to predict metastatic from non-metastatic PCa.
mong PCa with metastasis in comparison to PCa patients with-
ut metastases. ROC analyses for the prognostic power of serum
iRNA-141 yielded an AUC of 0.855 with 69% sensitivity and
4% specificity in differentiating patients with metastatic PCa from
on-metastatic group. This goes in agreement with Brase et al. that
emonstrated microRNA-141 to be considerably higher in serum
amples from patients with metastasized tumor when compared to
hose with localized tumour [13]. The surge of microRNA-141 in
etastatic cancer could be explained by its role in influencing mes-
nchymal to epithelial transition (MET), which is a key process
n metastatic colonization at distant sites. microRNA-141 allows
ET through direct targeting of Zeb1 (zinc finger E-box binding
omeobox 1) which is a transcriptional activator of the protein adhe-
ion molecule E-Cadherin. Expression of E-Cadherin reinforces
pithelial traits of the cell. Overexpression of microRNA-141 in
isseminated tumor cells allows cells to regain epithelial traits, thus
nhancing metastatic colonization in secondary organs [20,21] .
hang et al. found that serum microRNA-141 levels were elevated
n patients with bone-metastatic PCa and that patients with higher
evels of serum microRNA-141 developed more bone lesions. Fur-
hermore, serum microRNA-141 levels were correlated with serum
lkaline phosphatase but not serum PSA [22]. Liu et al. recently
ublished that microRNA-141 is downregulated in metastatic PCa
atients [23].n another cohort of 21 prostate cancer patients, Gonzales et al.














microRNA-141 and prostate cancer 
variations of other biomarkers of prostate cancer disease, such as
prostate specific antigen (PSA), circulating tumor cells (CTC) and
lactate dehydrogenase (LDH) [24]. In our study; microRNA-141
was significantly correlating with serum PSA and Gleason score. In
contrast to our study, Kachakova et al. did not observe correlation
of microRNA-141 with the clinic-pathological characteristics. Also,
they showed downregulation of microRNA-141 in a high percent of
PCa patients in comparison with BPH controls [25]. Also, Baffa et al.
compared 43 primary tumors (colon, bladder, breast and lung) to
their matched lymph node metastases showed that microRNA-141
was down-regulated in metastatic cancers [26].
Our study suggests that microRNA-141 may have an important diag-
nostic role for patients with mildly elevated PSA refusing prostatic
biopsies or as a non-invasive tool for patients with high PSA and neg-
ative prostatic biopsy to help for future management plans. Its value
was much higher than PSA in predicting the presence of metastatic
disease which is essential in patients’ management and to trigger
further radiological studies.
Our study, to our knowledge, is the first study to look for the possible
role of microRNA-141 on prostate cancer on Arabic and African
populations, however; its weakness represented in the relatively
small number of patients. Large scale prospective clinical stud-
ies are required to assess prognostic relevance of microRNA-141
to disease outcome and treatment response. The capacity of these
microRNA-141 to predict prostate cancer progression warrants fur-
ther validation also the detection of microRNA-141 levels in serial
samples after surgery or treatment are required.
Conclusion
microRNA-141 is a promising non-invasive tool which can help for
diagnostic dilemma of prostate cancer in some patients and higher
values are significantly correlating with the presence of metastatic
disease.
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